Methylphenidate hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Adults

MODIFIED RELEASE TABLETS (18, 27, 36 and 54mg):

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the recommendation to prescribe the branded generic Methylphenidate modified release preparations (18, 27, 36 and 54mg) with the lowest acquisition cost.
Such products have an AMBER traffic light status and are the preferred alternatives to Concerta®.  
- See the "Branded generic methylphenidate letters" for information for patients and clinicians
N.B. This guidance does not apply to other strengths of modified release methylphenidate as these have different release characteristics

Information on management of ADHD medication stock shortages

There are currently supply disruptions affecting various medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD).

A national patient safety alert has been issued and we have been liaising with colleagues both regionally and nationally about the ongoing situation.  We have been advised that centrally they are looking at publishing further guidance but until this is published we have been working with colleagues from Surrey & Borders Partnership NHS Trust and the Local Pharmaceutical Committee to produce the pack below which provides useful information and clinical recommendations about how to manage these shortages.  See resources titled "ADHD Medication Shortage"